<DOC>
	<DOCNO>NCT02251067</DOCNO>
	<brief_summary>The purpose study determine whether VPI-2690B Injection effective treatment diabetic nephropathy .</brief_summary>
	<brief_title>Phase 2 Study Evaluate Safety &amp; Efficacy VPI-2690B Diabetic Nephropathy Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>document diabetic nephropathy patient either Type 1 Type 2 diabetic HbA1c 7.510.5 % eGFR 30110 mL/min/1.73m2 stable ACEi/ARB dose regimen stable blood pressure BMI le equal 45 kg/m2 nondiabetic renal disease history solid organ islet cell transplant history malignancy within previous 5 year systemic immunosuppression therapy clinically significant liver disease , hepatitis B C HIV monoclonal antibody treatment within previous year recent acute renal injury major surgery significant , recent body weight change biopsy proven glomerular disease</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>